National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos®) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes.


NCPE Assessment Process Complete
Rapid review commissioned 28/09/2018
Rapid review completed 08/11/2018
Rapid Review outcome A Full Pharmacoeconomic Assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE 14/11/2018
Pre-submission consultation with Applicant 15/01/2019
Submission received from Applicant 31/05/2019
Current Status HTA submission received